Table 5.

Univariate association between covariates of interest and mortality outcomes

Overall mortalityLymphoma-specific mortality
HR (95% CI)PHR (95% CI)P
EBV+ status2.9 (1.4–5.6)<0.013.9 (1.6–9.4)<0.01
Age (per-year increase)1.0 (1.0–1.0)0.731.0 (1.0–1.1)0.81
Female gender2.6 (0.9–7.4)0.083.3 (1.0–11.3)0.06
Hispanic ethnicity1.7 (0.8–3.6)0.151.4 (0.8–3.8)0.54
Clinical stage
 LocalizedRefRef
 Regional1.3 (0.5–3.8)0.594.0 (0.8–19.7)0.09
 Distant1.3 (0.6–3.1)0.552.7 (0.6–12.0)0.21
Extranodal involvement: disseminated1.7 (0.7–4.0)0.253.9 (0.9–17.6)0.07
DLBCL subtype
 CentroblasticRef
 Immunoblastic1.4 (0.6–3.2)0.481.5 (0.5–4.9)0.46
 Plasmablastic4.2 (1.6–11.3)<0.018.5 (2.9–25.4)<0.01
Germinal center phenotype0.6 (0.3–1.2)0.161.0 (0.4–2.4)0.95
Elevated serum LDH4.2 (1.3–14.1)0.022.7 (0.8–9.4)0.12
ECOG performance status ≥22.5 (1.2–5.5)0.025.1 (2.0–13.0)<0.01
Presence of B symptoms1.3 (0.6–2.7)0.551.9 (0.8–4.9)0.17
IPI
 0–1 (low-risk)RefRef
 2 (low-intermediate risk)0.9 (0.2–3.6)0.880.9 (0.2–4.9)0.90
 3 (high-intermediate risk)2.6 (1.0–7.3)0.062.3 (0.7–8.2)0.19
 4–5 (high-risk)3.5 (1.1–11.5)0.044.1 (1.0–16.4)0.05
Prior AIDS diagnosis2.9 (1.5–5.8)<0.013.8 (1.5–9.5)<0.01
CD4 cell count ≥200/mm30.4 (0.2–0.9)0.020.4 (0.1–1.1)0.08